Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2016 1
2018 1
2019 2
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for Peter F. c gram
Your search for Peter F. Cogram retrieved no results
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Husain M, et al. N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11. N Engl J Med. 2019. PMID: 31185157 Clinical Trial.
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M. Bain SC, et al. Diabetes Obes Metab. 2019 Mar;21(3):499-508. doi: 10.1111/dom.13553. Epub 2018 Nov 11. Diabetes Obes Metab. 2019. PMID: 30284349 Free PMC article. Clinical Trial.
Characterization of the O-Glycoproteome of Tannerella forsythia.
Veith PD, Scott NE, Reynolds EC. Veith PD, et al. mSphere. 2021 Oct 27;6(5):e0064921. doi: 10.1128/mSphere.00649-21. Epub 2021 Sep 15. mSphere. 2021. PMID: 34523981 Free PMC article.
Tannerella forsythia is a Gram-negative oral pathogen known to possess an O-glycosylation system responsible for targeting multiple proteins associated with virulence at the three-residue motif (D)(S/T)(A/I/L/V/M/T). ...Glycosylation site analysis revealed that glycosylati …
Tannerella forsythia is a Gram-negative oral pathogen known to possess an O-glycosylation system responsible for targeting multiple p …
A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens.
Weyant KB, Oloyede A, Pal S, Liao J, Jesus MR, Jaroentomeechai T, Moeller TD, Hoang-Phou S, Gilmore SF, Singh R, Pan DC, Putnam D, Locher C, de la Maza LM, Coleman MA, DeLisa MP. Weyant KB, et al. Nat Commun. 2023 Jan 28;14(1):464. doi: 10.1038/s41467-023-36101-2. Nat Commun. 2023. PMID: 36709333 Free PMC article.
Engineered outer membrane vesicles (OMVs) derived from Gram-negative bacteria are a promising technology for the creation of non-infectious, nanoparticle vaccines against diverse pathogens. ...
Engineered outer membrane vesicles (OMVs) derived from Gram-negative bacteria are a promising technology for the creation of non-infe …
Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.
Chen L, Valentine JL, Huang CJ, Endicott CE, Moeller TD, Rasmussen JA, Fletcher JR, Boll JM, Rosenthal JA, Dobruchowska J, Wang Z, Heiss C, Azadi P, Putnam D, Trent MS, Jones BD, DeLisa MP. Chen L, et al. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3609-18. doi: 10.1073/pnas.1518311113. Epub 2016 Jun 6. Proc Natl Acad Sci U S A. 2016. PMID: 27274048 Free PMC article.
For example, expression of a 17-kb O-PS gene cluster from the highly virulent Francisella tularensis subsp. tularensis (type A) strain Schu S4 in hypervesiculating E. coli cells yielded glycOMVs that displayed F. tularensis O-PS. Immunization of BALB/c mice with gly …
For example, expression of a 17-kb O-PS gene cluster from the highly virulent Francisella tularensis subsp. tularensis (type A) strain Schu …
Botulinum toxin: a new differential diagnosis for a lytic bone lesion.
Lefkovits Y, Lipton L. Lefkovits Y, et al. J Med Case Rep. 2024 Mar 24;18(1):179. doi: 10.1186/s13256-024-04430-5. J Med Case Rep. 2024. PMID: 38521935 Free PMC article.
BACKGROUND: Botulinum toxin, produced by the Gram-positive anaerobe Clostridium botulinum, is composed of seven antigenic subtypes (A, B, C, D, E, F, and G). ...
BACKGROUND: Botulinum toxin, produced by the Gram-positive anaerobe Clostridium botulinum, is composed of seven antigenic subtypes (A …
Advantage of combining resin with lytic BACTEC blood culture media.
Rohner P, Pepey B, Auckenthaler R. Rohner P, et al. J Clin Microbiol. 1997 Oct;35(10):2634-8. doi: 10.1128/jcm.35.10.2634-2638.1997. J Clin Microbiol. 1997. PMID: 9316921 Free PMC article. Clinical Trial.
We compared two media for this system, resin-containing Plus aerobic/F and Lytic anaerobic/F. Sets of Plus aerobic/F and Lytic anaerobic/F vials inoculated with similar volumes (9 +/- 2.5 ml) were evaluated. ...Plus aerobic/F and Lytic anaerobic …
We compared two media for this system, resin-containing Plus aerobic/F and Lytic anaerobic/F. Sets of Plus aerobic/F an …